ACAD vs GMAB: fair value comparison
Acadia Pharmaceuticals Inc. and Genmab A/S · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ACAD currently sits closer to the top of our ranking by discount to fair value. ACAD carries the stronger quality grade.
| ACAD | GMAB | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $19.12 | $37.00 |
| 12-month range | $18.62–$30.57 | $23.85–$38.48 |
| Rank by discount to fair value | #74 of 108 Healthcare | #76 of 108 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ACAD fair value analysis · GMAB fair value analysis